Title: Quest Diagnostics: Svp & chief commercial officer Mark E Delaney bought 25 shares

Short description: Quest Diagnostics' svp & chief commercial officer Mark E Delaney bought 25 shares at $235.94 on Oct 21, 2026 for $5,899.

Summary: What happened Mark E Delaney, svp & chief commercial officer, acquired 25 shares of Quest Diagnostics at $235.94 per share on Oct 21, 2026, for a total of $5,899. The transaction is marked "L" for late in the filing.

Key details

• Transaction date and price: Oct 21, 2026 at $235.94 per share; 25 shares; total $5,899.
• Form filed on Oct 23, 2026.
• Shares owned after the transaction: not stated in the filing.
• Footnote F1: the filing says the shares were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and were eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report the transaction early on this Form 4.
• Transaction timeliness: L (late filing).

Why it may matter

• The filing indicates the shares were acquired via a dividend reinvestment plan administered by the reporting person's broker (not a direct market purchase).
• A filing does not show why the insider traded or why the company acted.